Jefferies Financial Group Inc. Purchases New Holdings in Penumbra, Inc. (NYSE:PEN)

Jefferies Financial Group Inc. purchased a new position in shares of Penumbra, Inc. (NYSE:PEN - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 3,200 shares of the company's stock, valued at approximately $760,000.

A number of other large investors also recently bought and sold shares of the stock. Gotham Asset Management LLC purchased a new stake in shares of Penumbra during the 4th quarter valued at $275,000. Fred Alger Management LLC purchased a new stake in Penumbra during the fourth quarter valued at about $710,000. Covenant Partners LLC acquired a new stake in Penumbra during the fourth quarter worth about $216,000. Crestline Management LP acquired a new stake in Penumbra during the fourth quarter worth about $332,000. Finally, Brevan Howard Capital Management LP purchased a new position in shares of Penumbra in the 4th quarter worth about $253,000. Hedge funds and other institutional investors own 88.88% of the company's stock.

Penumbra Stock Performance

PEN stock traded up $0.21 on Monday, reaching $280.89. The company's stock had a trading volume of 347,155 shares, compared to its average volume of 440,161. Penumbra, Inc. has a 52 week low of $148.00 and a 52 week high of $310.00. The company has a market capitalization of $10.88 billion, a P/E ratio of 826.15, a price-to-earnings-growth ratio of 2.83 and a beta of 0.53. The firm has a fifty day moving average of $279.37 and a two-hundred day moving average of $263.96. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.01 and a quick ratio of 3.25.

Penumbra (NYSE:PEN - Get Free Report) last released its earnings results on Wednesday, April 23rd. The company reported $0.83 EPS for the quarter, beating the consensus estimate of $0.66 by $0.17. Penumbra had a net margin of 1.17% and a return on equity of 9.74%. The firm had revenue of $324.14 million for the quarter, compared to analysts' expectations of $315.72 million. Penumbra's quarterly revenue was up 16.3% on a year-over-year basis. During the same quarter last year, the company earned $0.41 EPS. As a group, analysts predict that Penumbra, Inc. will post 3.67 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Thomas Wilder sold 360 shares of the company's stock in a transaction on Monday, March 31st. The stock was sold at an average price of $264.58, for a total transaction of $95,248.80. Following the completion of the sale, the director now directly owns 4,533 shares of the company's stock, valued at $1,199,341.14. This represents a 7.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Johanna Roberts sold 600 shares of the stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $287.43, for a total value of $172,458.00. Following the completion of the transaction, the executive vice president now owns 66,539 shares of the company's stock, valued at $19,125,304.77. This trade represents a 0.89% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 176,696 shares of company stock valued at $50,207,745 over the last quarter. Corporate insiders own 4.20% of the company's stock.

Analysts Set New Price Targets

A number of analysts recently issued reports on the stock. Robert W. Baird increased their target price on shares of Penumbra from $316.00 to $325.00 and gave the stock an "outperform" rating in a research report on Thursday, April 24th. BTIG Research reissued a "buy" rating on shares of Penumbra in a research note on Thursday, April 24th. Truist Financial lifted their target price on shares of Penumbra from $315.00 to $330.00 and gave the company a "buy" rating in a report on Thursday, April 24th. UBS Group restated a "buy" rating and issued a $330.00 price target (up previously from $320.00) on shares of Penumbra in a report on Thursday, April 24th. Finally, Bank of America initiated coverage on shares of Penumbra in a research report on Friday, March 14th. They issued a "buy" rating and a $320.00 price objective for the company. Three investment analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $302.40.

Penumbra Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.